Featured Research

from universities, journals, and other organizations

Temple University Researchers Develop New Targeted Cancer Therapy

Date:
April 10, 2005
Source:
Temple University Health Sciences Center
Summary:
Temple University researchers have developed a new drug that halts cancer cell division, instigating tumor death. The drug works by interfering with the activity of a gene called Plk1 and is now in phase I clinical trials for human cancer therapy.

Temple University researchers have developed a new drug that halts cancer cell division, instigating tumor death. The drug works by interfering with the activity of a gene called Plk1 and is now in phase I clinical trials for human cancer therapy. Their research is published in the March issue of Cancer Cell.

Related Articles


Plk1 is one of several molecules that play a critical role in the spread of cancer. Previous studies have found higher levels of Plk1 in cancer tumors and in patients with poorer survival rates. When Plk1 activity was blocked, cancer cells could not divide and tumors could not survive.

Led by Prem Reddy, Ph.D., professor of biochemistry and director of the Fels Institute for Cancer Research at Temple University School of Medicine, the Temple team sought out a new compound that would target and block Plk1. They developed and tested ON01910, a small molecule that inhibits Plk1 activity, on 94 different human cancers. "We found that ON01910 was a potent inhibitor of human tumor growth and also worked well with several existing cancer drugs, often inducing complete regression of tumors. Someday it might work either as a single drug or in combination with other drugs," said Reddy.

Johns Hopkins Medicine and Mt. Sinai Medical Center are currently conducting the first clinical trial of ON01910 in patients with advanced and metastatic cancers. The studies will evaluate data from up to 56 patients. ON01910 is known as a targeted therapy, a new area of cancer drug research and development. As the name suggests, such therapies target molecules that are critical to a tumor's survival. Targeted therapies block the molecules from functioning, thereby preventing tumors from surviving.

On the unique actions of ON01910, Reddy said, "Our drug stops tumor cells from reaching normal cells three ways. First, it blocks invasion, next it blocks angiogenesis and finally, it induces tumor cell death. It also appears to be very safe." Other research team members are Kiranmai Gumireddy1, M.V. Ramana Reddy, Stephen C. Cosenza1, R. Boomi Nathan, Stacey J. Baker, Nabisa Papathi1, Jiandong Jiang, and James Holland.


Story Source:

The above story is based on materials provided by Temple University Health Sciences Center. Note: Materials may be edited for content and length.


Cite This Page:

Temple University Health Sciences Center. "Temple University Researchers Develop New Targeted Cancer Therapy." ScienceDaily. ScienceDaily, 10 April 2005. <www.sciencedaily.com/releases/2005/03/050326095452.htm>.
Temple University Health Sciences Center. (2005, April 10). Temple University Researchers Develop New Targeted Cancer Therapy. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2005/03/050326095452.htm
Temple University Health Sciences Center. "Temple University Researchers Develop New Targeted Cancer Therapy." ScienceDaily. www.sciencedaily.com/releases/2005/03/050326095452.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Rural India's Low-Cost Sanitary Pad Revolution

Rural India's Low-Cost Sanitary Pad Revolution

AFP (Nov. 28, 2014) — One man hopes his invention -– a machine that produces cheap sanitary pads –- will help empower Indian women. Duration: 01:51 Video provided by AFP
Powered by NewsLook.com
Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) — In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins